Kyowa Kirin Archives | Be Korea-savvy

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases

The licensed small molecule program aims to address significant unmet needs for autoimmune diseases. Program adds to Boehringer’s pipeline and its commitment to deliver breakthrough therapies for patients with inflammatory diseases. Ingelheim, Germany, and Tokyo, Japan, [October 30, 2025] – Boehringer Ingelheim and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and COO: Abdul Mullick) today announced that Boehringer Ingelheim has licensed a pre-clinical program from Kyowa Kirin to develop [...]

Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress

Princeton, NJ and TOKYO, Sept. 11, 2025 (Korea Bizwire) — Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cell rebalancing therapy, will be presented as a late breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) 2025 Annual Meeting to [...]